Shares of Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) rose 10.8% during trading on Wednesday . The stock traded as high as $4.63 and last traded at $4.50, with a volume of 73,447 shares. The stock had previously closed at $4.06.

Several brokerages have recently issued reports on CATB. Cowen and Company reaffirmed a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. Wedbush reaffirmed an “outperform” rating and set a $17.00 price target (down previously from $27.00) on shares of Catabasis Pharmaceuticls in a research note on Tuesday, June 7th. Zacks Investment Research raised Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Tuesday, July 5th. Finally, Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $28.00 price target on shares of Catabasis Pharmaceuticls in a research note on Wednesday, May 25th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $19.05.

The company’s market cap is $69.95 million. The firm’s 50-day moving average is $3.81 and its 200-day moving average is $4.98.

Catabasis Pharmaceuticls (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($0.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.03. On average, equities research analysts expect that Catabasis Pharmaceuticls Inc. will post ($2.52) EPS for the current fiscal year.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.